Tvardi’s next-generation STAT3 inhibitor TTI-109 confirmed rapid prodrug conversion, dose-proportional exposure, and improved tolerability versus TTI-101 in Phase 1 testing. Investorideas.com (www.investorideas.com) a trusted platform for investing ideas, including biotech…
Tag:
